☆ 4.6 Article

Somatic Mutation of the Non-Muscle-Invasive Bladder Cancer Associated with Early Recurrence

DIAGNOSTICS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Health Policy & Services

Socio-economic burden of disease: Survivorship costs for bladder cancer

Julia Caroline Michaeli et al.

Summary: In this study, the socio-economic burden of bladder cancer survivorship in Germany was analyzed for the ten years after initial treatment. The results showed that follow-up costs increased, with significant differences depending on the risk level and tumor stage. Insurers covered a smaller proportion of the costs, and medical resources were mainly consumed by physician-patient visits and medical imaging. This highlights the importance of cancer survivorship for the healthcare system and society and the need to consider it in cost-effectiveness evaluations.

JOURNAL OF CANCER POLICY (2022)

添加到收藏夹

Review Urology & Nephrology

European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)

Marko Babjuk et al.

Summary: The updated EAU guidelines provide new information on the diagnosis and treatment of NMIBC for clinical practice. Individual risk assessment is crucial in determining the appropriate treatment for patients with different risk levels. Surgical intervention, including radical cystectomy, may be necessary for cases unresponsive to BCG treatment or with high risk of progression.

EUROPEAN UROLOGY (2022)

添加到收藏夹

Article Oncology

Somatic Features of Response and Relapse in Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guerin Immunotherapy

Jack V. W. Bacon et al.

Summary: This study investigates the association between genomic alterations and BCG resistance in high-risk NMIBC, and identifies ARID1A mutation and CCNE1 amplification as potential predictors of relapse. Pre- and post-BCG tumors share common driver alterations, but somatic profiles can change over time. The findings highlight the importance of recent biopsy in considering targeted therapies.

EUROPEAN UROLOGY ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Oncomine™ Comprehensive Assay v3 vs. Oncomine™ Comprehensive Assay Plus

Lau K. Vestergaard et al.

Summary: The detection of genetic alterations in cancer is crucial for tailoring personalized treatments. The study compared the performance of gene mutations identified by OCA-Plus and OCAv3, showing a 91% concordance in pathogenic variants. The OCA-Plus can reflect the mutational profile of genomic variants compared with OCAv3 of 144 overlapping genes, without compromising performance.

CANCERS (2021)

添加到收藏夹

Article Multidisciplinary Sciences

An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer

Sia Viborg Lindskrog et al.

Summary: Non-muscle-invasive bladder cancer shows large biological heterogeneity, with transcriptomic analysis identifying four classes that reflect disease aggressiveness and patient outcomes. Chromosomal instability, p53 pathway disruption, and APOBEC-related mutations are significantly associated with tumor class 2a and poorer outcomes.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis

Ryota Tamura

Summary: Neurofibromatosis is a neurocutaneous syndrome characterized by tumors in the nervous system, with NF1, NF2, and SWN as its three main types. While NF1 and NF2 have known genetic mutations and targeted therapies, the molecular mechanisms of SWN remain unclear and require further research.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Medicine, General & Internal

Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study

Md Ismail Hosen et al.

EBIOMEDICINE (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer

Jia Lv et al.

BIOSCIENCE REPORTS (2020)

添加到收藏夹

Article Oncology

Epidermal Growth Factor Receptor (EGFR) Cell Expression During Adjuvant Treatment After Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A New Potential Tool to Identify Patients at Higher Risk of Disease Progression

Fabrizio Di Maida et al.

CLINICAL GENITOURINARY CANCER (2019)

添加到收藏夹

Article Oncology

Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017 A Systematic Analysis for the Global Burden of Disease Study

Christina Fitzmaurice et al.

JAMA ONCOLOGY (2019)

添加到收藏夹

Article Urology & Nephrology

Genomic classification and risk stratification of bladder cancer

Damiano Fantini et al.

WORLD JOURNAL OF UROLOGY (2019)

添加到收藏夹

Review Urology & Nephrology

Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers

Gladell P. Paner et al.

EUROPEAN UROLOGY (2018)

添加到收藏夹

Article Urology & Nephrology

Prognostic significance of epidermal growth factor receptor (EGFR) over expression in urothelial carcinoma of urinary bladder

Atif Ali Hashmi et al.

BMC UROLOGY (2018)

添加到收藏夹

Article Urology & Nephrology

Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets

Eugene J. Pietzak et al.

EUROPEAN UROLOGY (2017)

添加到收藏夹

Review Urology & Nephrology

Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review

Viktor Soukup et al.

EUROPEAN UROLOGY (2017)

添加到收藏夹

Review Biochemistry & Molecular Biology

Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification

Rick Kamps et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)

添加到收藏夹

Article Oncology

AACR Project GENIE: Powering Precision Medicine through an International Consortium

Fabrice Andre et al.

CANCER DISCOVERY (2017)

添加到收藏夹

Article Oncology

Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency

Carolyn D. Hurst et al.

CANCER CELL (2017)

添加到收藏夹

Article Oncology

Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma

Jakob Hedegaard et al.

CANCER CELL (2016)

添加到收藏夹

Article Urology & Nephrology

EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin

Samantha Cambier et al.

EUROPEAN UROLOGY (2016)

添加到收藏夹

Article Urology & Nephrology

Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline

Sam S. Chang et al.

JOURNAL OF UROLOGY (2016)

添加到收藏夹

Review Oncology

ATM Mutations in Cancer: Therapeutic Implications

Michael Choi et al.

MOLECULAR CANCER THERAPEUTICS (2016)

添加到收藏夹

Article Oncology

TERT Promoter Mutations Occur Early in Urothelial Neoplasia and Are Biomarkers of Early Disease and Disease Recurrence in Urine

Isaac Kinde et al.

CANCER RESEARCH (2013)

添加到收藏夹

Article Multidisciplinary Sciences

Signatures of mutational processes in human cancer

Ludmil B. Alexandrov et al.

NATURE (2013)

添加到收藏夹

Article Multidisciplinary Sciences

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

Patrick J. Killela et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)

添加到收藏夹

Article Urology & Nephrology

Bladder cancer: Epidemiology, staging and grading, and diagnosis

Z Kirkali et al.

UROLOGY (2005)

添加到收藏夹

Article Oncology

EGFR and cancer prognosis

RI Nicholson et al.

EUROPEAN JOURNAL OF CANCER (2001)

添加到收藏夹

Article Urology & Nephrology

Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group study

DL Lamm et al.

JOURNAL OF UROLOGY (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.